SFI
KYMR icon

Susquehanna Fundamental Investments’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-59,436
Closed -$2.39M – 1159
2024
Q4 		$2.39M Buy
+59,436
New +$2.68M 0.03% 484
2024
Q2 		$2.29M Buy
76,818
+5,325
+7% +$184K 0.05% 382
2024
Q1 		$2.87M Buy
+71,493
New +$2.56M 0.13% 187

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna Fundamental Investments's KYMR Position: Q1 2025 in Review

Susquehanna Fundamental Investments sold out of Kymera Therapeutics (KYMR) in Q1 2025, closing a stake of 59,436 shares — an estimated $2.39M sold.

Susquehanna Fundamental Investments first reported a position in KYMR in Q1 2024 and held it in 3 quarters. The position peaked at $2.87M in Q1 2024. 173 funds tracked by Wall St. Rank hold KYMR as of Q1 2025.

  • Susquehanna Fundamental Investments reported no remaining Kymera Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 59,436 Kymera Therapeutics shares in Q1 2025, an estimated $2.39M.
  • Susquehanna Fundamental Investments first reported a position in Kymera Therapeutics in Q1 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Kymera Therapeutics position peaked at $2.87M in Q1 2024.
  • 173 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2025, filed 14 May 2025.